Medical/Pharmaceuticals
MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients
GENEVA, Aug. 16, 2023 /PRNewswire/ -- MedAlliance has announced completion of patient enrollment in the SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in renal dialysis patients. SELUTION SLR is a novel sirolimus-...
2023-08-16 08:00
3281
Transcenta to Present Three Study Results at ESMO 2023
SUZHOU, China, Aug. 16, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to ...
2023-08-16 08:00
3218
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biop...
2023-08-16 05:00
3534
CStone Pharmaceuticals Reports 2023 Interim Results and Updates
* The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of pharmaceutical products revenue was RMB 246.9 million, representing a growth rate of 53% compared to the same period last year. Commercial gross profit margin improved from 47% to 59%. * Healthy fin...
2023-08-15 22:33
5962
Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI)
SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase in...
2023-08-15 20:19
4710
Leading Asia Pacific Biopharmas Power Digital Engagement with Veeva CRM
Eighteen of the top 20 biopharmas standardize with Veeva to build meaningful
customer relationships
SINGAPORE, Aug. 15, 2023 /PRNewswire/ -- Veeva Systems
2023-08-15 09:00
5421
TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan
Non-profit drug developer partners with leading manufacturer of medicine in Pakistan NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medici...
2023-08-14 21:30
2639
UMP Introduces Artificial Intelligence Technology for Enhanced Chest X-Ray Analysis Efficiency
HONG KONG, Aug. 14, 2023 /PRNewswire/ -- UMP Healthcare Holdings Limited ("UMP " or the "Group", stock code: 722.HK) is pleased to announce the signing of a memorandum of understanding (MOU) withImsight Technology Company Limited, specialised in providing artificial intelligence (AI) medical imag...
2023-08-14 15:45
3592
Kelun-Biotech announces that a Phase III clinical trial of core product SKB264 (MK-2870, TROP2-ADC) in patients with unresectable locally advanced, recurrent or metastatic TNBC who have failed second-line or above prior standard of care has met its primary endpoint
CHENGDU, China, Aug. 14, 2023 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. ("Kelun-Biotech", HKEX: 6990.HK) announced today that its innovative TROP2-ADC (SKB264, also known as MK-2870) met the primary endpoint in the randomized, controlled, open-label, multi-center Phase III ...
2023-08-14 12:50
6492
Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach
PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a$1M contract spanning two years (HHSF223018186...
2023-08-11 21:14
4691
Move Aside Anti-Ageing, It's Age Reversal We're Talking Now
SINGAPORE, Aug. 11, 2023 /PRNewswire/ -- In the realm of medical progress, the horizon extends far beyond the battle against diseases. Now, the concept of "age reversal" — not merely slowing down or halting ageing — stands as a tangible reality. However, the validity and accuracy of ageing measur...
2023-08-11 13:49
3055
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...
2023-08-11 11:14
3034
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China
- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and improving access of the drug to patients in the mainland ofChina - Antengene to receive up to RMB200 million in upfront payments,...
2023-08-11 08:00
4138
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...
2023-08-11 07:18
3215
YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023
GAITHERSBURG, Md., Aug. 10, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-08-11 04:30
5771
LyondellBasell Awarded the 2023 Global Medical Plastics Company of the Year by Frost & Sullivan
LyondellBasell is among the top three global polyolefin manufacturers in terms of capacity and sustainable solutions, catering to multiple industries, including pharmaceuticals and medical devices. SAN ANTONIO, Aug. 10, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the medical plasti...
2023-08-10 19:00
2752
AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reduction in patient-reported Subjective Units of Distress Scale (SUDS) score compared to placebo in a public speaking challenge (primary endpoint, p...
2023-08-10 15:49
6682
Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]
* First pneumococcal conjugate vaccine that fights against 20 serotypes leading to most of the invasive pneumococcal diseases and pneumonia[2],[3] — one of the leading causes of death inHong Kong[4] — has been approved by Hong Kong Department of Health inApril 2023 and is now available in Hong ...
2023-08-10 14:15
3123
![Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]](https://mma.prnasia.com/media2/2155046/Pfizer.jpg?p=medium600)
APRIL Group partners the Indonesian Ministry of Health to elevate primary healthcare levels in Riau province
SINGAPORE, Aug. 10, 2023 /PRNewswire/ -- The Indonesian Ministry of Health (Kemenkes) and Asia Pacific Resources International Limited (APRIL) Group signed a Memorandum of Understanding (MOU) on25 July 2023 at PT. RAPP (Riau Andalan Pulp and Paper) facility - a business unit of APRIL Group. For ...
2023-08-10 12:43
2842
Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting
SUZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that posters to highlight the company's core pipeline products, PD-L1/CTLA-4 bispecific antibody KN046 and HER2 bispecific antibody KN026, will beannounced at the 2023 European Society for Medical Oncol...
2023-08-10 09:02
3760
Week's Top Stories
Most Reposted
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 275 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 270 media titles]
2026-10-22 11:55Carro Establishes Inaugural SGD450 Million Asset-Backed Securitisation Warehouse Facility
[Picked up by 267 media titles]
2026-10-22 11:00Ready Server Launches ReadyServer LLM API, Giving Every VPS Customer Private AI Inference at No Extra Cost
[Picked up by 265 media titles]
2026-10-20 14:10Most Read
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
2026-10-19 13:18
10862
FinDev Canada provides a USD 60 million loan to Muangthai Capital to advance gender equality and private sector investment in Thailand
2026-10-17 00:54
10691
BUUU Group Limited Announces 10-for-1 Forward Share Split
2026-10-17 04:30
10020